Global Parkinson’s Disease Market 2025–2029: Competitive Insights and Opportunities

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Global Market Value Of The Parkinson’s Disease Industry In 2025?

The Parkinson’s disease market has shown strong growth in recent years. It is anticipated to expand from $3.34 billion in 2024 to $3.62 billion in 2025, achieving a compound annual growth rate (CAGR) of 8.2%. The historical increase in the market can be linked to factors such as increasing research and development, growth in government funding, the emergence of personalized treatment plans, the expansion of support networks for Parkinson’s disease patients, and the rising application of advanced rehabilitation therapies.

The market for Parkinson’s disease is projected to experience robust expansion over the coming years, anticipated to reach $4.94 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 8.1%. Factors contributing to this growth during the forecast period include greater recognition of Parkinson’s disease symptoms, increased governmental programs, higher expenditure on healthcare, an expanding number of Parkinson’s disease clinical trials, and the growing uptake of gene therapies. Key trends shaping the forecast period encompass advancements in technology, government-led initiatives and financial support, the application of artificial intelligence in diagnostics, novel solutions, and personalized medical approaches.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21247&type=smp

Which Drivers Are Supporting Growth Of The Parkinson’s Disease Market?

The expanding presence of neurodegenerative diseases is anticipated to fuel the growth of the parkinson’s disease market in the future. Neurodegenerative diseases are conditions marked by the progressive deterioration and loss of function of neurons within the brain and nervous system. The escalation in the occurrence of these diseases is attributed to factors such as an aging population, genetic predisposition, environmental influences, enhanced diagnosis, increasing chronic health conditions, and lifestyle changes. Parkinson’s disease facilitates a deeper understanding of neurodegenerative diseases by offering crucial perspectives on their underlying mechanisms, potential therapeutic targets, and the creation of innovative treatment approaches. For instance, in April 2022, data from the European Brain Council, a Belgium-based non-profit organization, revealed that over 600 neurological diseases and nearly 300 psychiatric conditions impact millions globally, including 65 million with epilepsy. In Europe, 10.5 million people have dementia, with projections indicating a rise to 18.7 million by 2050. Consequently, the increasing prevalence of neurodegenerative diseases is stimulating the expansion of the parkinson’s disease market.

What Are The Different Segment Classifications Within The Parkinson’s Disease Market?

The parkinson’s diseasemarket covered in this report is segmented –

1) By Drug Class: Dopamine Agonists; Catechol-O-Methyltransferase Inhibitors; Monoamine Oxidase B Inhibitors; Anticholinergics; Carbidopa-Levodopa; Other Drug Classes

2) By Route Of Administration: Oral; Injectable; Intestinal infusion; Subcutaneous; Other Route Of Administrations

3) By Distribution Channel: Retail Pharmacies; Hospital Pharmacies; Online Pharmacies

4) By Patient Care Setting: Clinics; Hospitals

Subsegments:

1) By Dopamine Agonists: Ergot Derivatives; Non-Ergot Derivatives

2) By Catechol-O-Methyltransferase (COMT) Inhibitors: Entacapone; Tolcapone; Opicapone

3) By Monoamine Oxidase B (MAO-B) Inhibitors: Selegiline; Rasagiline; Safinamide

4) By Anticholinergics: Trihexyphenidyl; Benztropine; Procyclidine

5) By Carbidopa-Levodopa: Immediate-Release Formulation; Extended-Release Formulation; Inhaled And Intestinal Gel Formulations

6) By Other Drug Classes: Amantadine And Derivatives; Adenosine A2A Receptor Antagonists; Glutamate Antagonists

What Are The Latest Industry Trends Transforming The Parkinson’s Disease Market?

Leading companies in the Parkinson’s disease market are prioritizing the development of innovative treatments, such as levodopa-based therapy, to enhance motor function and ensure continuous symptom management for individuals with advanced Parkinson’s disease. Levodopa-based therapy involves administering levodopa, a medication that converts into dopamine in the brain, to improve motor function and alleviate symptoms of Parkinson’s disease. As an illustration, in October 2024, AbbVie Inc., a US-based biopharmaceutical company, obtained US Food and Drug Administration (FDA) approval for VYALEV, a combination therapy comprising levodopa and carbidopa, specifically developed for the treatment of Parkinson’s disease. Its design aims to increase levodopa’s effectiveness by preventing its breakdown before it reaches the brain, thereby elevating dopamine levels. This medication proves beneficial in controlling motor symptoms of Parkinson’s disease, including tremors, rigidity, and bradykinesia, which consequently improves a patient’s ability to perform daily activities. It is regarded as a crucial therapeutic option for Parkinson’s disease patients who experience motor fluctuations.

Which Key Players Are Driving Competition In The Parkinson’s Disease Market?

Major companies operating in the parkinson’s disease market are Roche Holding AG, AbbVie Inc., Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, UCB S.A., Eisai Co. Ltd., Kyowa Kirin Co. Ltd., Amneal Pharmaceuticals Inc., Neurocrine Biosciences Inc., Supernus Pharmaceuticals Inc., Sunovion Pharmaceuticals Inc., Intracellular Therapies Inc., Voyager Therapeutics Inc., Sage Therapeutics Inc., Adamas Pharmaceuticals Inc., Sun Pharma Advanced Research Company Ltd., Neuraly Inc., Mitsubishi Tanabe Pharma Corporation, Athira Pharma Inc., VistaGen Therapeutics Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/parkinsons-disease-global-market-report

Which Region Currently Holds The Largest Share Of The Parkinson’s Disease Market?

North America was the largest region in the parkinson’s disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the parkinson’s disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Parkinson’s Disease Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21247&type=smp

Browse Through More Reports Similar to the Global Parkinson’s Disease Market 2025, By The Business Research Company

Autoimmune Disease Diagnosis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report

Alzheimer Disease Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/alzheimer-disease-treatment-global-market-report

Chronic Disease Management Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-disease-management-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795